A single dose of psilocybin, the major hallucinogenic component in magic mushrooms, induces long-lasting decreases in anxiety and depression in patients diagnosed with life-threatening cancer according to a new study presented today at the annual meeting of the American College of Neuropsychopharmacology.
Patients who receive a cancer diagnosis often develop debilitating symptoms of anxiety and depression. Reports from the 1960s and 1970s suggest that hallucinogenic drugs such as LSD may alleviate such symptoms in cancer patients, but the clinical value of hallucinogenic drugs for the treatment of mood disturbances in cancer patients remains unclear. In this new study, Roland Griffiths and colleagues from the Johns Hopkins University School of Medicine investigated the effects of psilocybin on symptoms of anxiety and depression in individuals diagnosed with life-threatening cancer. Five weeks after receiving a dose of psilocybin sufficiently high to induce changes in perception and mystical-type experiences, patients reported significantly lower levels of anxiety and depression compared with patients that received a low dose of the drug. The positive effects on mood persisted in the patients at 6 month follow-up.
The authors suggest that a single dose of psilocybin may be sufficient to produce enduring decreases in negative mood in patients with a life-threatening cancer.
Read more:Â Active ingredient in magic mushrooms reduces anxiety and depression in cancer patients
The Latest on: Psilocybin
via Google News
The Latest on: Psilocybin
- Union County Board of Commissioners may ask voters to approve psilocybin opt out ordinanceon August 1, 2022 at 3:25 pm
LA GRANDE — Union County voters in November may be given the chance to virtually ban psilocybin products in much of the county. The Union County Board of Commissioners is set to vote on an ordinance ...
- Canadian State-Funded Trial Looks To Understand If Psychedelia Is Necessary For The Therapeutic Effect Of Psilocybinon July 29, 2022 at 2:33 pm
Mental health and addiction teaching hospital and research center CAMH has recently been awarded Canada's first federal grant by the Canadian Institutes of Health Research (CIHR) to study psilocybin ...
- Author Michael Pollan, with eye on Oregon’s psilocybin rollout, talks about plant-derived drugson July 29, 2022 at 9:07 am
Michael Pollan has spent much of his career writing about the sometimes surprising relationship between plants and humans. His newest book, “This Is Your Mind on Plants,” focuses on three different ...
- Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compoundon July 28, 2022 at 1:19 pm
Psychedelics mental healthcare company Compass Pathways PLC. (NASDAQ: CMPS) has launched a phase 2 clinical study testing the efficacy of psilocybin with psychological support in people with anorexia ...
- Canada-Based Project Solace Aims To Provide Access And Data On Medical Psilocybinon July 28, 2022 at 7:04 am
TheraPsil, a Canadian coalition for psilocybin therapy legalization, together with the U.K. independent foundation Drug Science, has launched Project Solace.
- Biden Administration ‘Exploring’ Psychedelics Task Force Ahead Of Expected Federal Approval Of Psilocybin And MDMAon July 27, 2022 at 1:41 pm
A top federal health agency says it is actively “exploring” the possibility of creating a task force to investigate the therapeutic of certain psychedelics like psilocybin and MDMA in anticipation of ...
- New study looks at 'magic' mushrooms as treatment for depression, without the psychedelic highon July 27, 2022 at 10:21 am
A new study by the Centre for Addiction and Mental Health (CAMH) will attempt to harness the antidepressant power of psilocybin mushrooms, but without the psychedelic experience. Psilocybin is the ...
- CAMH receives first Canadian federal (CIHR) grant to study psilocybinon July 27, 2022 at 3:09 am
More specifically, researchers will explore whether experiencing psilocybin's psychedelic effects are required for it to have antidepressant effects. "There has been a growing interest and body of ...
- Psychedelic Rx: Legal battles aim to expand patients' access to psilocybin and other hallucinogenson July 26, 2022 at 11:32 am
This is really diving into the whole emotional side and finding mental clarity and spiritual ease around everything, because life will throw you a lot of things that you have to manage, like a death ...
- Global Psilocybin Assisted Therapy Market is Expected to Grow at a CAGR of 9.2% over the Forecast Periodon July 25, 2022 at 8:41 am
Psilocybin, sometimes known as magic mushrooms, is a natural chemical that has hallucinogenic characteristics when consumed. They belong to the psychedelic drug class, which causes alterations in ...
via Bing News